CD70 knockdown in GB cells significantly reduces tumorigenicity in vitro and in vivo, and CD70 CAR-T therapy enhances survival rates in animal models, indicating a robust immune response against CD70-expressing GBs [18]. Here, CD70 is linked to Guillain-Barre syndrome.